CO5660275A2 - Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 - Google Patents
Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5Info
- Publication number
- CO5660275A2 CO5660275A2 CO05126935A CO05126935A CO5660275A2 CO 5660275 A2 CO5660275 A2 CO 5660275A2 CO 05126935 A CO05126935 A CO 05126935A CO 05126935 A CO05126935 A CO 05126935A CO 5660275 A2 CO5660275 A2 CO 5660275A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitor
- pde5
- pde4
- phosphodiesterase
- disease
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 6
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 6
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 6
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 6
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011609 | 2003-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5660275A2 true CO5660275A2 (es) | 2006-07-31 |
Family
ID=33462087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05126935A CO5660275A2 (es) | 2003-05-22 | 2005-12-16 | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20060094723A1 (enExample) |
| EP (1) | EP1628682B1 (enExample) |
| JP (1) | JP2006528229A (enExample) |
| KR (1) | KR20060012004A (enExample) |
| CN (1) | CN1791429A (enExample) |
| AU (1) | AU2004241749B2 (enExample) |
| BR (1) | BRPI0410326A (enExample) |
| CA (1) | CA2525946C (enExample) |
| CO (1) | CO5660275A2 (enExample) |
| EA (1) | EA012279B1 (enExample) |
| EC (1) | ECSP056173A (enExample) |
| GE (1) | GEP20084342B (enExample) |
| IL (1) | IL171306A (enExample) |
| IS (1) | IS8181A (enExample) |
| MA (1) | MA27855A1 (enExample) |
| MX (1) | MXPA05012302A (enExample) |
| NO (1) | NO333501B1 (enExample) |
| NZ (1) | NZ544040A (enExample) |
| RS (1) | RS52730B (enExample) |
| TN (1) | TNSN05265A1 (enExample) |
| UA (1) | UA83041C2 (enExample) |
| WO (1) | WO2004103407A2 (enExample) |
| ZA (1) | ZA200508116B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| MXPA04008070A (es) | 2003-03-10 | 2004-11-26 | Altana Pharma Ag | Novedoso proceso para la preparacion de roflumilasto. |
| WO2005023253A1 (en) | 2003-09-05 | 2005-03-17 | Altana Pharma Ag | Use of pde4 inhibitors for the treatment of diabetes mellitus |
| WO2005107749A1 (en) * | 2004-05-10 | 2005-11-17 | Altana Pharma Ag | Use of roflumilast for the prophylaxis or treatment of emphysema |
| MX2007010560A (es) * | 2005-03-08 | 2008-02-21 | Nycomed Gmbh | Roflumilast para el tratamiento de diabetes mellitus. |
| WO2006094942A1 (en) * | 2005-03-08 | 2006-09-14 | Nycomed Gmbh | Roflumilast for the treatment of diabetes mellitus |
| US8663694B2 (en) | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
| CA2604295C (en) * | 2005-04-19 | 2014-10-07 | Nycomed Gmbh | Roflumilast for the treatment of pulmonary hypertension |
| NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| UA106422C2 (uk) * | 2006-07-05 | 2014-08-26 | Такеда Гмбх | КОМБІНОВАНЕ ЗАСТОСУВАННЯ ІНГІБІТОРА PDE4 ТА ІНГІБІТОРА HMG-CоA-РЕДУКТАЗИ ДЛЯ ПРОФІЛАКТИКИ АБО ЗЦІЛЮВАЛЬНОГО ЛІКУВАННЯ ЗАПАЛЬНОГО ЗАХВОРЮВАННЯ ЛЕГЕНІВ |
| CN101547922B (zh) * | 2006-10-04 | 2012-06-20 | 辉瑞产品公司 | 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物 |
| WO2010013925A2 (en) * | 2008-07-31 | 2010-02-04 | Dong-A Pharmaceutical. Co., Ltd. | Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof |
| JP2014526461A (ja) * | 2011-09-09 | 2014-10-06 | エスケー ケミカルズ カンパニー，リミテッド | Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物 |
| JP6225178B2 (ja) * | 2012-05-31 | 2017-11-01 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体ＲＯＲγの調整剤としてのカルボキサミドまたはスルホンアミド置換されたチアゾールおよび関連する誘導体 |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| EP3165224A1 (en) | 2015-11-09 | 2017-05-10 | Albert-Ludwigs-Universität Freiburg | Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders |
| US10058545B2 (en) * | 2016-08-09 | 2018-08-28 | Cipla Limited | Method of treating pulmonary arterial hypertension |
| CN107648224A (zh) * | 2017-10-31 | 2018-02-02 | 泰州中国医药城中医药研究院 | 一种治疗和预防心力衰竭药物及其在制药中的应用 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| CN108976107B (zh) * | 2018-08-23 | 2021-03-23 | 南方医科大学 | 3-芳基-4-烷氧基苄胺衍生物及其制备方法和应用 |
| WO2020106704A2 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230124467A1 (en) * | 2020-03-03 | 2023-04-20 | Mios Pharmaceuticals Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| HU220041B (hu) | 1993-07-02 | 2001-10-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Fluor-alkoxi-helyettesített benzamidszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| EP0779292A4 (en) * | 1994-08-29 | 1997-09-24 | Yamanouchi Pharma Co Ltd | NEW NAPHTHYRIDE DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEM |
| US6127363A (en) * | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| US6417190B1 (en) * | 1998-12-17 | 2002-07-09 | Boehringer Ingelheim Pharma Kg | Tricyclic nitrogen heterocycles as PDE IV inhibitors |
| TWI224966B (en) * | 1999-11-02 | 2004-12-11 | Pfizer | Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient |
| EA200300836A1 (ru) * | 2001-02-15 | 2004-02-26 | Алтана Фарма Аг | Производные фталазинон-пиперидина в качестве ингибиторов pde4 |
| AU2002314102A1 (en) * | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| GB0202254D0 (en) * | 2002-01-31 | 2002-03-20 | Pfizer Ltd | Prevention of scarring |
| US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
-
2004
- 2004-05-19 CA CA2525946A patent/CA2525946C/en not_active Expired - Fee Related
- 2004-05-19 UA UAA200511710A patent/UA83041C2/ru unknown
- 2004-05-19 EP EP04766017.0A patent/EP1628682B1/en not_active Expired - Lifetime
- 2004-05-19 CN CNA2004800133493A patent/CN1791429A/zh active Pending
- 2004-05-19 KR KR1020057021796A patent/KR20060012004A/ko not_active Ceased
- 2004-05-19 BR BRPI0410326-2A patent/BRPI0410326A/pt active Search and Examination
- 2004-05-19 RS YU20050858A patent/RS52730B/sr unknown
- 2004-05-19 EA EA200501690A patent/EA012279B1/ru not_active IP Right Cessation
- 2004-05-19 US US10/556,888 patent/US20060094723A1/en not_active Abandoned
- 2004-05-19 JP JP2006530210A patent/JP2006528229A/ja active Pending
- 2004-05-19 WO PCT/EP2004/050869 patent/WO2004103407A2/en not_active Ceased
- 2004-05-19 AU AU2004241749A patent/AU2004241749B2/en not_active Ceased
- 2004-05-19 GE GEAP20049115A patent/GEP20084342B/en unknown
- 2004-05-19 NZ NZ544040A patent/NZ544040A/en not_active IP Right Cessation
- 2004-05-19 MX MXPA05012302A patent/MXPA05012302A/es active IP Right Grant
-
2005
- 2005-10-07 ZA ZA200508116A patent/ZA200508116B/en unknown
- 2005-10-09 IL IL171306A patent/IL171306A/en not_active IP Right Cessation
- 2005-10-18 TN TNP2005000265A patent/TNSN05265A1/en unknown
- 2005-11-17 EC EC2005006173A patent/ECSP056173A/es unknown
- 2005-12-12 MA MA28653A patent/MA27855A1/fr unknown
- 2005-12-14 IS IS8181A patent/IS8181A/is unknown
- 2005-12-14 NO NO20055941A patent/NO333501B1/no not_active IP Right Cessation
- 2005-12-16 CO CO05126935A patent/CO5660275A2/es active IP Right Grant
-
2010
- 2010-05-24 US US12/785,973 patent/US20100234382A1/en not_active Abandoned
-
2012
- 2012-04-12 US US13/445,675 patent/US20120196867A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1628682A2 (en) | 2006-03-01 |
| NO20055941L (no) | 2005-12-14 |
| RS20050858A (sr) | 2007-12-31 |
| AU2004241749A1 (en) | 2004-12-02 |
| RS52730B (sr) | 2013-08-30 |
| MXPA05012302A (es) | 2006-01-30 |
| UA83041C2 (ru) | 2008-06-10 |
| CA2525946C (en) | 2013-01-29 |
| ECSP056173A (es) | 2006-04-19 |
| EP1628682B1 (en) | 2013-09-25 |
| TNSN05265A1 (en) | 2007-07-10 |
| MA27855A1 (fr) | 2006-04-03 |
| US20100234382A1 (en) | 2010-09-16 |
| NZ544040A (en) | 2009-03-31 |
| BRPI0410326A (pt) | 2006-05-23 |
| IL171306A (en) | 2013-08-29 |
| JP2006528229A (ja) | 2006-12-14 |
| CN1791429A (zh) | 2006-06-21 |
| US20120196867A1 (en) | 2012-08-02 |
| AU2004241749B2 (en) | 2010-03-25 |
| KR20060012004A (ko) | 2006-02-06 |
| WO2004103407A3 (en) | 2005-02-17 |
| EA200501690A1 (ru) | 2006-06-30 |
| WO2004103407A2 (en) | 2004-12-02 |
| ZA200508116B (en) | 2007-01-31 |
| CA2525946A1 (en) | 2004-12-02 |
| GEP20084342B (en) | 2008-03-25 |
| EA012279B1 (ru) | 2009-08-28 |
| NO333501B1 (no) | 2013-06-24 |
| US20060094723A1 (en) | 2006-05-04 |
| IS8181A (is) | 2005-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5660275A2 (es) | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 | |
| ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
| AR077573A2 (es) | Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| ECSP099387A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| AR054094A1 (es) | Tratamientos de cancer | |
| CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| AR028959A1 (es) | Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares | |
| NZ577393A (en) | Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction | |
| AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
| UY26422A1 (es) | Método para administrar un inhibidor de fosfodiesterasa 4 | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| AR043327A1 (es) | Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes | |
| BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
| BRPI0508333A (pt) | uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit | |
| CO6470875A2 (es) | Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares | |
| BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
| AR052830A1 (es) | Regimen de cladribina para tratar esclerosis multiple | |
| UY28182A1 (es) | Uso de dipiridamol en combinación con ácido acetilsalicílico y un antagonista de angiotensina ii para la prevención de accidente cerebrovascular | |
| CR9444A (es) | Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |